Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results

OBJECTIVES: To evaluate 6-month effectiveness of ustekinumab versus tumour necrosis factor inhibitor (TNFi), analysing predictors of low disease activity (LDA)/remission. METHODS: PsABio is a prospective, observational cohort study of patients with psoriatic arthritis (PsA) at 92 sites in eight Euro...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Siebert, Stefan, Korotaeva, Tatiana V, Selmi, Carlo, Bergmans, Paul, Gremese, Elisa, Joven-Ibáñez, Beatriz, Katsifis, Gkikas, Noël, Wim, Nurmohamed, Michael T, Richette, Pascal, Sfikakis, Petros P, de Vlam, Kurt, Theander, Elke, Gossec, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522461/
https://www.ncbi.nlm.nih.gov/pubmed/34162594
http://dx.doi.org/10.1136/annrheumdis-2021-220263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522461/
https://www.ncbi.nlm.nih.gov/pubmed/34162594
http://dx.doi.org/10.1136/annrheumdis-2021-220263

Ejemplares similares